SERGIO RODRIGUES DE MORAES

(Fonte: Lattes)
Índice h a partir de 2011
3
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Coronary Artery Calcium Score and Risk of Cardiovascular Events in Heterozygous Familial Hypercholesterolemia Patients Undergoing Standard Lipid Lowering Therapy
    (2018) MINAME, Marcio; BITTENCOURT, Marcio S.; MORAES, Sergio R.; I, Romulo Alves; SILVA, Pamela R.; JANNES, Cinthia E.; PEREIRA, Alexandre C.; NASIR, Khurram; SANTOS, Raul D.
  • conferenceObject
    CORONARY ARTERY CALCIFICATION IS SUPERIOR TO CLASSICAL RISK FACTORS AS PREDICTOR OF CARDIOVASCULAR DISEASE IN FAMILIAL HYPERCHOLESTEROLEMIA
    (2018) MINAME, Marcio; ALVES, Romulo; MORAES, Sergio; SILVA, Pamela; BITTENCOURT, Marcio; JANNES, Cinthia; PEREIRA, Alexandre; SANTOS, Raul
  • conferenceObject
    Coronary artery calcification is an independent predictor of cardiovascular events in familial hypercholesterolemia
    (2017) MINAME, M. H.; SILVA, P. R. S.; ALVES, R. L. M.; MORAES, S. R.; BITTENCOURT, M. S.; ROCHA, V. Z.; MARTE, A. P.; SALGADO, W.; JANNES, C. E.; PEREIRA, A. C.; SANTOS, R. D.
  • article 9 Citação(ões) na Scopus
    Acute administration of oestradiol or progesterone in a spinal cord ischaemia-reperfusion model in rats
    (2018) CAVALCANTE, Leonardo Pessoa; FERREIRA, Sueli Gomes; PEREIRA, Daniel Romano; MORAES, Sergio Rodrigues de; SIMAS, Rafael; SANNOMIYA, Paulina; BREITHAUPT-FALOPPA, Ana Cristina; MOREIRA, Luiz Felipe Pinho
    OBJECTIVES: Despite research into protective pharmacological adjuncts, paraplegia persists as a dreaded complication after thoracic and thoracoabdominal aortic interventions. Reports on gender-related neurological outcomes after ischaemic and traumatic brain injuries have led to increased interest in hormonal neuroprotective effects and have generated other studies seeking to prove the neuroprotective effects of the therapeutic administration of 17 beta-oestradiol and of progesterone. We hypothesised that acute administration of oestradiol or progesterone would prevent or attenuate spinal cord ischaemic injury induced by occlusion of the descending thoracic aorta. METHODS: Male rats were divided into groups receiving 280 A mu g/kg of 17 beta-oestradiol or 4 mg/kg of progesterone or vehicle 30 min before transitory endovascular occlusion of the proximal descending thoracic aorta for 12 min. Hindlimb motor function was assessed by a functional grading scale (that of Basso, Beattie and Bresnahan) for 14 days after reperfusion. On the 14th day, a segment of the thoracolumbar spinal cord was harvested and prepared for histological and immunohistochemical analyses. RESULTS: There was significant impairment of the motor function of the hindlimb in the 3 study groups, with partial improvement noticed over time, but no difference was detected between the groups. On Day 1 of assessment, the 17 beta-oestradiol group had a functional score of 9.8 (0.0-16.5); the progesterone group, a score of 0.0 (0-17.1) and the control group, a score of 6.5 (0-16.9); on the 14th day, the 17 beta-oestradiol group had a functional score of 18.0 (4.4-19.4); the progesterone group had a score of 7.5 (0-18.5) and the control group had a score of 17.0 (0-19.9). Analysis of the grey matter showed that the number of viable neurons per section was not different between the study groups on the 14th day. Immunostaining of the spinal cord grey matter was also similar among the 3 groups. CONCLUSIONS: Acute administration of oestradiol or of progesterone 30 min before transitory occlusion of the proximal descending thoracic aorta of male rats could not prevent or attenuate spinal cord ischaemic injury based on an analysis of functional and histological outcomes.
  • article 105 Citação(ões) na Scopus
    Coronary Artery Calcium and Cardiovascular Events in Patients With Familial Hypercholesterolemia Receiving Standard Lipid-Lowering Therapy
    (2019) MINAME, Marcio H.; BITTENCOURT, Marcio Sommer; MORAES, Sergio R.; ALVES, Romulo I. M.; SILVA, Pamela R. S.; JANNES, Cinthia E.; PEREIRA, Alexandre C.; KRIEGER, Jose E.; NASIR, Khurram; SANTOS, Raul D.
    OBJECTIVES The aim of this study was to evaluate the role of coronary artery calcium (CAC) as a predictor of atherosclerotic cardiovascular disease (ASCVD) (fatal or not myocardial infarction, stroke, unstable angina requiring revascularization, and elective myocardial revascularization) events in asymptomatic primary prevention molecularly proven heterozygous familial hypercholesterolemia (FH) subjects receiving standard lipid-lowering therapy. BACKGROUND FH is associated with premature ASCVD. However, the clinical course of ASCVD in subjects with FH is heterogeneous. CAC score, a marker of subclinical atherosclerosis burden, may optimize ASCVD risk stratification in FH. METHODS Subjects with FH underwent CAC measurement and were followed prospectively. The association of CAC with ASCVD was evaluated using multivariate analysis. RESULTS A total of 206 subjects (mean age 45 +/- 14 years, 36.4% men, baseline and on-treatment low-density lipoprotein cholesterol 269 +/- 70 mg/dl and 150 +/- 56 mg/dl, respectively) were followed for a median of 3.7 years (interquartile range: 2.7 to 6.8 years). CAC was present in 105 (51%), and 15 ASCVD events (7.2%) were documented. Almost one-half of events were hard outcomes, and the others were elective myocardial revascularizations. The annualized rates of events per 1,000 patients for CAC scores of 0 (n = 101 [49%]), 1 to 100 (n = 62 [30%]) and >100 (n = 43 [21%]) were, respectively, 0, 26.4 (95% confidence interval: 12.9 to 51.8), and 44.1 (95% confidence interval, 26.0 to 104.1). In multivariate Cox regression analysis, log(CAC score 1) was independently associated with incident ASCVD events (hazard ratio: 3.33; 95% CI: 1.635 to 6.790; p = 0.001). CONCLUSIONS CAC was independently associated with ASCVD events in patients with FH receiving standard lipid-lowering therapy. This may help further stratify near-term risk in patients who might be candidates for further treatment with newer therapies. (C) 2019 by the American College of Cardiology Foundation.